54
Participants
Start Date
January 2, 2025
Primary Completion Date
March 31, 2026
Study Completion Date
August 31, 2026
LepVax (2 μg LEP-F1 + 5 μg GLA-S): Low dose
2 μg LEP-F1 + 5 μg GLA-SE will be administered by IM injection on Days 0,28, and 56 in healthy participants.
LepVax (10 μg LEP-F1 + 5 μg GLA-SE): High dose
10 μg LEP-F1 + 5 μg GLA-SE will be administered by IM injection on Days 0,28, and 56 in healthy participants.
Placebo Comparator: Placebo
Sterile normal saline for injection will be administered by IM injection on Days 0, 28, and 56 in healthy participants and paucibacillary leprosy patients.
Oswaldo Cruz Institue, Rio de Janeiro
Oswaldo Cruz Institute
UNKNOWN
The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
OTHER